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OBJETIVE: The objective of the present study was to evaluate the kinetic disposition of vancomycin in preterm infants with
emphasis on the apparent volume of distribution, biological half-life, and total body clearance as well as whether their variations
cause significant modification of the trough plasma concentration of the drug, depending on the postconceptional age (PCA) and
the postnatal age (PNA).
MATERIAL AND METHOD: Twenty-five selected patients were distributed into 2 groups which differed significantly in terms
of mean PCA (31.2-32.3 weeks in group 1, n = 13; 33.5-34.1 weeks in group 2, n = 12: CI95%, P < .001) and PNA (group 1, 12.0-
18.5 days; group 2, 18.0-34.0 days, CI95%, P < .05). The parents were informed and signed a written consent for participation of
the infants in the protocol that had been previously approved by the Ethics Committee of the hospital.
RESULTS: Apparent volume of distribution was significantly increased in group 1 compared with patients of group 2 (0.85 vs.
0.56 L/kg, respectively; P = .01,). Additionally multiple linear regression revealed a good linear correlation (r = 0.85) of trough
plasma concentration of vancomycin with the apparent volume of distribution and also with the biological half-life in patients of
group 1, while a good correlation (r = 0.91) was obtained for the trough plasma concentration with total body clearance in infants
of group 2. The influence of these kinetic parameters on the trough concentration of vancomycin in preterm infants seems to vary
according to PCA and PNA.
CONCLUSION: In conclusion, the trough plasma concentration of vancomycin depends on the pharmacokinetics, and multiple
linear correlation indicates that it varies according to the postconceptional and postnatal age of preterm infants.
KEYWORDS: Pharmacokinetics. Vancomycin. Preterm infants.
INTRODUCTION
One of the main agents of nosocomial infections in
preterm infants is Staphylococcus species.1–3 About 70% of
Staphylococcus species have been found to be methycillin
resistant in the Neonatal Intensive Care Unit of the Uni-
versity Hospital of Sao Bernardo do Campo, Faculty of
Medicine of ABC. Vancomycin is the best alternative for
these oxacillin-resistant agents. In general, the peak con-
centration of the drug ranges from 20 to 40 µg/mL and the
trough concentration ranges from 5 to 10 µg/mL. However,
if the plasma concentration reaches peak values higher than
40 µg/mL or trough higher than 10 µg/mL, very serious
adverse effects, ototoxicity and nephrotoxicity, respectively,
can be expected.4–6
Regarding the analytical method for the plasma vanco-
mycin measurements, fluorescence polarization immu-
noassay (FPIA) has been applied in most of the previously
published studies.7–10 Nowadays, it is well known that this
method is rapid but presents low selectivity; its degrada-
tion product, which is structurally quite similar to vanco-
mycin, is produced in vitro and also in vivo, interfering with
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the immunoassay, because the kit does not contain the
monoclonal antibody.
Some additional studies have been developed to compare
FPIA and high performance liquid chromatography (HPLC)
for plasma vancomycin measurements in patients with sep-
sis.11–13 All authors reported lower plasma levels of vanco-
mycin (peak and trough) using HPLC compared with FPIA,
indicating the higher selectivity of the HPLC method. Good
correlation of laboratory data and clinical efficacy were re-
ported for infants with sepsis by Staphylococcus species.11–13
Although pharmacokinetic data for vancomycin for
pediatric patients and preterm infants are rare, a wide
interindividual variation has been reported when the same
dose was administered, resulting in poorly predictable
plasma vancomycin concentrations. Interference of renal
function with vancomycin elimination and changes in body
water compartments are the main characteristics in the
growing individual, and these variations might be explained
according to the age of preterm infants.4–6,14,15 Therefore, the
objective of the present study was to investigate the kinetic
disposition of vancomycin in preterm infants and also the
influence of apparent volume of distribution (Vd), biologi-
cal half-life (t½β), and total body clearance (Clt) on the
trough plasma concentration (Css
min) of vancomycin.
METHODS
Study design, ethics, and drug administration
A prospective cohort study was conducted on 25 preterm
infants with sepsis who differed significantly in terms of
postconceptional age (PCA) and postnatal age (PNA) and
who were accordingly distributed into 2 groups. Sepsis was
in a similar phase in both groups of investigated infants,
because vancomycin was prescribed in a earlier stage of
hospitalization, and the criteria for deciding which dose
should be prescribed for neonatal patients was based on the
Young and Mangun (2001) dose prescription for infants in
the intensive care unit (ICU).
The clinical study was developed in the hospital’s
neonatal ICU, and the analytical procedure and statistics
were performed in a research laboratory for clinical trials
in a public university.
The protocol of the study was submitted and approved
by the Ethics Committee of the hospital’s medical school
in 2001. Patients from the ICU were included in the study,
vancomycin was administered by fast infusion for a mini-
mum of 3 days to reach the steady state, and a series of
blood samples were collected by the same physician from
all patients investigated. The clinical protocol was com-
pleted in about 1 year, beginning at the end of 2001 and
ending the end of 2002. Each infant was followed during
the protocol for a period of 4 days (3 days of drug therapy
with vancomycin plus 1 day for blood collection), and then
the treatment was optimized and continued up to the dis-
charge of infant from the ICU.
Inclusion and exclusion criteria were as follows:
• Inclusion criteria: < 35 weeks postconceptional age;
clinical diagnosis of sepsis, and/or blood culture posi-
tive for Staphylococcus species; use of vancomycin,
combined or not combined with other antimicrobial
agents or vasoactive or diuretic drugs.
• Exclusion criteria: Apgar score ≤ 5 at 5 minutes of life;
congenital renal anomaly; previous use of indometh-
acin; history of edema, altered renal function, or
hemodynamic instability.
Gestational age was based on the date of the last men-
struation or on the New Ballard method.17
For group 1, gestational age ranged from 28.9 to 30.2
weeks (95%CI), with a mean of 29.5 ± 1.1 weeks. The mean
PCA was 31.8 ± 0.9 weeks (95%CI: 31.2-32.3 weeks) and
the mean PNA was 15.3 ± 5.9 days (95%CI: 12-18.5 days).
The mean birth body weight was 1184 ± 283 g (95%CI:
1030-1338 g), whereas the mean body weight at the time
of sample collection was 1232 ± 263 g (1089-1375 g).
Mean creatinine clearance was 30 ± 19 mL/min/1.73 m2
(95%CI: 22.3- 37.3).
In group 2, the mean gestational age was 30.1 ± 1.9
weeks (95%CI: 29-31.2 weeks). The mean PCA was 33.8
± 0.5 weeks (95%CI: 33.5-34.1 weeks) and the mean PNA
was 26 ± 14.2 days (95%CI: 18-34 days). The mean birth
weight of the infants was 1175 ± 308.4 g (95%CI: 1000-
1350 g), whereas the mean weight at the time of sample
collection was 1289 ± 265 g (1140-1440 g). With respect
to renal function, mean creatinine clearance was 31.4
± 17.2 mL/min/1.73 m2 (95%CI: 24.6- 38.1).
Except for PCA and PNA, no significant differences were
found between groups for any of these parameters (Table 1).
Table 1 - Characteristics of infants investigated: comparison
of experimental groups.
Parameter IC95%(mean)
Group 1 n = 13 Group 2 n = 13 Probabilitya
CA (weeks) 28.9-30.2(29.5) 29.0-31.2(30.1) .40
PCA (weeks) 31.2-32.3(31.8) 33.5-34.1(33.8) < .001
PNA (days) 12.0-18.5(15.3) 18.0-34.0(26.0) .02
Birth weight (g) 1030-1338(1184) 1000-1350(1175) .94
Birth height (cm) 36-39.5(37.7) 36.4-40.4(38.4) .55
CA: conceptional age, PCA: postconceptional age, and PNA: postnatal age.
Statistical significance, P < .05, Student t test for unpaired data.
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Vancomycin doses of 10, 15, or 20 mg/kg were admin-
istered at dose intervals of 8, 12, or 18 h, respectively.
Twenty-five patients were allocated into group 1 (n = 13),
or group 2 (n = 12) as determined by the PCA and PNA.
The dose schedules of vancomycin administered for each
patient investigated are described in Table 2.
Before drug administration, vancomycin was diluted in
5% dextrose solution, and was administered by an infusion
pump over a 1-hour period.
After 3 days of antibiotic therapy, samples of venous
blood (1 mL) were collected from a peripheral blood vein
by the physician in the neonatal unit of the medical school
hospital for the determination of the plasma vancomycin
concentration at steady state.
Blood samples for each infant were collected at 0, 1, 2,
4, and 6 h and immediately before the next infusion, or at
the trough concentration, at the 8th, 12th or 18th hour, de-
pending on dosing schedule (Table 2).
In addition, mean creatinine clearances estimated from
serum creatinine were 30.0 mL/min/1.73 m2 (IC 95%: 22.3-
37.3) in group 1 and 31.4 mL/min/1.73 m2 (IC 95%: 24.6-
38.1) in group 2, which are considered normal values for
preterm infants < 34 weeks according to PNA.
Before the start of the study, the parents of the infants
signed a voluntary informed consent form, and the proto-
col was approved by the Ethics Committee of the hospital.
Analytical procedure, pharmacokinetics, and statistics.
Vancomycin in plasma was analyzed using a selective
micromethod requiring only 0.2 mL of biological matrix
and determined by an automated high-performance liquid
chromatographic method (HPLC-UV) under the supervision
of a pharmacist from the laboratory.12,13
For pharmacokinetics, a 1-compartment open model was
applied, and the kinetic parameters were estimated using
the PK Solutions® 2.0 software (Noncompartmental Phar-
macokinetics Data Analysis) Ashland, OH, USA. Statisti-
cal analysis was based on the Student t test using the
GraphPad InStat® 2.01, Graphpad Software Corporation,
San Diego, USA, GMC Basic® 6.6, Ribeirão Preto, SP, Bra-
zil. Multiple linear regression was obtained by applying the
SPSS® software, 9.0 Chicago, USA.
RESULTS
A wide variation was observed in vancomycin plasma
concentrations in both groups of infants as listed in Table
3, which shows the percentage of patients of both groups
with emphasis on their peak and trough levels. Regarding
the trough plasma concentration for vancomycin in both
groups of patients investigated, plasma levels were observed
in the recommended range (5-10 µg/mL) in a higher per-
centage in patients of group 1 (7/13) compared with group
2 (4/12), 54% vs. 33%, respectively. Infants of both groups
investigated were under subtherapy in similar percentages
(23%, 3/13, group 1 vs. 17%, 2/12, group 2). In addition,
a potential risk of nephrotoxicity related to trough levels
higher than 10 µg/mL was observed in 23% (3/13) of group
1 vs. 50% (6/12) of group 2. These results could be ex-
plained as a consequence of water compartment (extravas-
cular/interstitial fluid), which was increased in infants of
group 1 compared with infants of group 2. Therefore, lower
trough vancomycin levels were obtained for infants of group
1 compared to group 2.
With respect to peak levels, plasma vancomycin con-
centrations obtained were higher than 40 µg/mL, and a po-
tential risk of ototoxicity was present for 23% (3/13) of the
infants in group 1, Table 3.
Peak plasma concentrations of vancomycin were in the
recommended range (20-40 µg/mL) in 23% patients (3/13)
of group 1 vs. 75% (9/12) of patients from group 2. In ad-
dition, peaks lower than 20 µg/mL were obtained in 54%
(7/13) of patients from group 1 vs. 25% (3/12) in group 2.
These data also indicate that the water compartments were
increased in infants from group 1 compared to those from
group 2, since vancomycin plasma levels in group 1 were
lower than in group 2.
Regarding clinical efficacy, high percentages were ob-
Table 2 – Dose schedule of vancomycin administered to
preterm infants of groups 1 and 2
Dose /period Time dose Infants of Infants of
interval(hours) Group 1 (n=13) Group 2 (n=12)
10 mg/kg 8 - 7
15 mg/kg 12 9 3
20 mg/kg 18 4 2
Table 3 - Distribution of patients (groups 1 and 2) based on
the peak and the trough plasma levels
Plasma level Percentage
Group 1 (n=13) Group 2 (n=12)
Trough < 5mg/mL 23% (3/13) 17% (2/12)
5-10 mg/mL 54% (7/13) 33% (4/12)
>10 mg/mL 23% (3/13) 50% (6/12)
Peak < 20mg/mL 54% (7/13) 25% (3/12)
20-40 mg/mL 23% (3/13) 75% (9/12)
> 40 mg/mL 23% (3/13) 0% (0/12)
Recommended ranges: 20-40 mg/mL (peak) and 5-10 mg/mL (trough)
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tained for patients of group 1 (77%: 10/13) and of group 2
(83%: 10/12) after the treatment minimum of 3 days with
vancomycin infusion over a 1-hour period; then if neces-
sary, dose adjustment was performed after this period to
optimize drug therapy.
Vancomycin pharmacokinetic data including peak and
trough levels are shown in Table 4 (mean, CI95%), compar-
ing the parameters of both groups of patients investigated.
Peak and trough values did not show significant differences
between groups because of the wide interindividual variation
of data in both groups of patients. Similarly, the biological
half-life and plasma clearance were not significantly differ-
ent between groups. The apparent volume of distribution was
increased in patients from group 1 compared with those from
group 2, indicating an inverse change of water compartment
related to PNA and PCA in preterm infants.
The influence of pharmacokinetics on the vancomycin
trough was shown in group 1, using multiple linear regres-
sion. The mathematical model (r: 0.85) included Vd and
t½ β as independent variables, whereas Clt was excluded.
The following equation was used and the standard devia-
tion of the constants and of the partial regression coeffi-
cients of Equation 1 were as follows:
Css
min = 9.05 - 14.50(Vd) + 1.23(t½ β) (1)
Where:
9.05 is a constant,
14.5 and 1.23 are the partial regression coefficients
standard deviation of the constant ± 3.89, and of the par-
tial regression coefficients of Equation 1 were ± 3.13 (Vd)
and ± 0.32 (t½ β), respectively.:
In group 2, the model that describes the data obtained
includes Clt (r: 0.91), while the Vd and t½ β were excluded
as follows in the equation 2:
Css
min = 18.22 – 9.27(Clt) (2)
Where:
18.22 is a constant,
9.27 is the partial regression coefficient
the standard deviations of the constant and of the partial
regression coefficient of Equation 2 were ± 1.30 and ± 1.31
(Clt), respectively.
DISCUSSION
The 2 population samples investigated differed statisti-
cally only in terms of PCA (P = .01) and PNA (P = .02);
they are more homogenous than those reported in the pre-
vious studies.14,18–21
The trough plasma concentration of vancomycin seems
to be the most important parameter for drug monitoring
since it is directly related to the therapeutic efficacy of the
antibiotic agent. The adequate value is based on the blood
level that must exceed by 2 to 8 times the minimal inhibi-
tory concentration for Staphylococcus species.22
In the present study, the percentage of infants with
plasma concentrations in the therapeutic range for the peak
or the trough were dependent on the group considered.
In general, the clinical consequences of the overdose of
vancomycin therapy are mainly transitory nephrotoxicity or
permanent ototoxicity with potential risks in children. In
the present study, the potential risk of transitory nephro-
toxicity was confirmed in both groups of patients investi-
gated, but they were lower than data reported previously.20
Additionally, based on the therapeutic drug monitoring fol-
lowed by the pharmacokinetic modelling, the dose adjust-
ment was performed by the physician to reach trough
plasma levels lower than 10 µg/mL to guarantee clinical
efficacy and no risk of nephrotoxicity.
Since the dosage adjustment was performed during the
first week of drug therapy, no potential risk of ototoxicity
occurred in infants included in the protocol, in spite of 23%
(3/13) reaching peak plasma levels higher than 40 µg/mL
only in patients from group 1. Then after 3 days of treat-
ment, if necessary, the daily dose was reduced based on
therapeutic drug monitoring. Since the peak plasma con-
centration of vancomycin was proportional to the dose and
the rate of drug infusion, data presented agree with results
reported by other investigators.23
The mean biological half-life of 11.3 hours (IC95%, 9.3-
13.3 hours) obtained for infants of group 1 (Table 4) agrees
with those reported previously for newborns of 32 weeks
or less PCA. However, it is important to emphasize that a
larger variation is reported for the parameter (3.5-25.5 h,
n = 44) in an investigation reported in a previous study.24
It should be noted that only the apparent volume of dis-
tribution differed significantly between groups (P = .01,
Table 4). These data indicate that PCA and PNA can sig-
nificantly influence the volume of distribution of vanco-
Table 4 - Pharmacokinetics of vancomycin in preterm infants
Parameter IC95%(mean)
Group 1 (n=13) Group 2 (n=12) Probability
Peak (mg/mL) 16.0-31.2 (23.6) 20.6-31.4 (26.0) .63
Trough (mg/mL) 5.4-15.7 (10.5) 8.1-11.8 (9.9) .96
t½ β (h) 9.3-13.3 (11.3) 6.7-10.8 (8.7) .50
Vd (L/Kg) 0.63-1.06 (0.85) 0.45-0.66 (0.56) .01
Clt (mL/min/kg) 0.70-1.20 (0.98) 0.70-1.07 (0.89) .69
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mycin to a greater degree than total body clearance (Clt);
consequently, if the PCA and PNA decrease, the Vd in-
creases.
Volume of distribution was found to be a good index
for dose adjustment in patients of group 1, while trough
levels in group 2 seemed to depend mainly on the glomeru-
lar filtration rate related to plasma clearance. These find-
ings could be explained by the higher distribution of drug
in preterm infants of  32 weeks PCA (group 1) compared
with those of 34 weeks PCA (group 2), based mainly on
the increased water compartment in infants of group 1.
Multiple linear regression was applied to analyze the
data and to determine which independent variables exerted
the influence on trough plasma vancomycin concentration.
Since the trough concentration depends on volume of dis-
tribution and, to a lesser extent, on t½ β in preterm infants
with PCA of 32 weeks, to optimize antimicrobial therapy,
Equation 1 should be applied to these cases. In contrast,
for infants of 34 weeks PCA, drug adjustments required for
the maintenance of trough concentration at therapeutic win-
dow depend on Clt according to Equation 2.
The main contribution of data obtained in the present
study is that a good correlation of pharmacokinetics of van-
comycin in both groups of infants investigated was shown
in a different manner, using the postconceptual age (PCA)
and also the postnatal age (PNA). In addition, the 2 popu-
lation samples investigated in the present study are more
homogenous than those reported in the previous studies.14,
18–21
 Data obtained here differed statistically only in terms
of PCA and PNA, P < .05.
Differences found in kinetic data obtained in this study
compared to published data could be explained by the selec-
tive and sensitive micromethod using HPLC applied to deter-
mine vancomycin concentrations in plasma of infants, since
in most of the information reported previously, the drug was
analyzed by a method using FPIA (fluorescence polarized im-
munoassay), which has a lower selectivity than the chromato-
graphic method applied to our study. It is well known that van-
comycin plus its degradation product have been quantified
without differentiation by FPIA, so that the plasma levels are
overestimated, with a significant error in the estimation of
plasma clearance and also the biological half-life. Previous
experience of our group shows that trough vancomycin levels
lower than 5 µg/mL obtained by the HPLC method were re-
lated to the failure of drug therapy Therefore, the therapeutic
drug monitoring of vancomycin is pharmacoeconomically fea-
sible and recommended for patients of all ages, more espe-
cially for infants and for the elderly under intensive care.7–10
Finally, the data reported in the present study indicate that
therapeutic drug monitoring is critical for these patients, and
the pharmacokinetic data must guide the neonatal physician
in dose adjustments to guarantee the success of pharmaco-
therapy of sepsis in infants with vancomycin.
CONCLUSION
The trough plasma concentrations of vancomycin in
preterm infants of group 1 depended mainly on volume of
distribution but also on biological half-life, while that pa-
rameter in group 2 depended only on the total body clear-
ance. Finally the influence of these kinetic parameters on
trough plasma vancomycin concentration in preterm infants
varies according to postconceptional age and postnatal age.
ACKNOWLEDGMENTS
To the Brazilian Research Support institutions, CAPES,
CNPq and FAPESP, for the financial support.
RESUMO
Machado JKK1, Feferbaum R1, Kobayashi CE2, Sanches C,
Santos SRCJ3. Farmacocinética da vancomicina em
neonatos pré-termo. CLINICS. 2007;62(4)405-10.
OBJETIVO: O objetivo do presente estudo foi investigar
a farmacocinética da vancomicina em neonatos pretermo,
considerando a idade pós-conceptual e também a idade pós-
natal para determinar se as alterações no volume aparente
de distribuição, meia-vida biológica e depuração plasmática
causam variação significativa no vale plasmático da
vancomicina.
MATERIAL E MÉTODO: Os vinte e cinco pacientes se-
lecionados foram distribuídos em dois grupos, que diferiram
significativamente em termos de idade pós-conceptualgrupo
1, n=13: 31,2-32,3 semanas; grupo 2, n=12: 33,5-34,1 se-
manas, IC95%, p<0,0001) e idade pós-natalgrupo 1: 12,0-
18,5 dias; grupo 2: 18,0-34,0 dias, p<0,05). Todos os res-
ponsáveis foram informados sobre os detalhes do estudo e
assinaram o termo de consentimento livre e esclarecido. O
protocolo foi submetido e aprovado previamente pelo Co-
mitê de Ética em Pesquisa do hospital.
RESULTADO: O volume aparente de distribuição se mos-
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trou significativamente aumentado no grupo 1 comparado
aos pacientes do grupo 2 0,85 vs 0,56 L/kg, p=0,01). Adi-
cionalmente, o teste de regressão linear múltipla mostrou
boa correlação linear: 0,85) da concentração plasmática de
vale com o volume aparente de distribuição, e também com
a meia-vida biológica nos pacientes do grupo 1. Nas cri-
anças do grupo 2 evidenciou-se boa correlação(r: 0,91) en-
tre o vale e a depuração plasmática. A influência desses
parâmetros farmacocinéticos sobre o vale nos prematuros
parece variar de acordo com a idade pós-conceptual e a ida-
de pós-natal.
CONCLUSÃO: Concluindo, a concentração de vale para
a vancomicina depende da farmacocinética e a correlação
múltipla varia de acordo com a idade pós-conceptual e a
idade pós-natal dos recém-nascidos pré-termos.
UNITERMOS: Farmacocinética. Vancomicina. Neonatos
pré-termos.
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